660,337 Danaher Corporation $DHR Shares Bought by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its stake in shares of Danaher Corporation (NYSE:DHR) by 7,466.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 669,181 shares of the conglomerate’s stock after acquiring an additional 660,337 shares during the period. Fort Washington Investment Advisors Inc. OH owned about 0.10% of Danaher worth $148,257,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. EP Wealth Advisors LLC bought a new position in shares of Danaher during the 2nd quarter worth approximately $3,807,000. Puzo Michael J acquired a new stake in shares of Danaher in the second quarter valued at approximately $8,624,000. First Nebraska Trust Co bought a new stake in shares of Danaher in the second quarter worth $14,106,000. Madison Asset Management LLC bought a new stake in shares of Danaher in the second quarter worth $85,451,000. Finally, Colton Groome Financial Advisors LLC acquired a new position in Danaher during the third quarter worth $592,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on DHR shares. Wells Fargo & Company reduced their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Royal Bank Of Canada lifted their price target on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. TD Cowen increased their price objective on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley raised their price target on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Stock Up 0.8%

Danaher stock opened at $224.65 on Thursday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company’s 50-day moving average price is $212.92 and its two-hundred day moving average price is $195.39. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market cap of $157.93 billion, a P/E ratio of 39.90, a P/E/G ratio of 2.80 and a beta of 0.76.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 earnings per share. As a group, analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio is 28.42%.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.